

Cleansing Statement Section 708A Notice

2 July 2018, Melbourne: Notice given under Section 708A(5)(e) of the Corporations Act 2001 (**Corporations Act**):

Integral Diagnostics Limited (the **Company**) (ASX: IDX) advises that it has today issued:

- 9,971,928 ordinary shares as part consideration for the Company's acquisition of Specialist Radiology Group, Trinity MRI and Cavendish Radiology in Auckland, New Zealand (announced to the market on 29 May 2018); and
- 376,682 ordinary shares as part consideration for the Company's acquisition of Geelong Medical Imaging (announced to the market on 1 June 2018),

(together the **New Shares**).

In accordance with section 708A(5)(e) of the Corporations Act, the Company advises that:

1. it has issued the New Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of this notice, the Company has complied with:
 - a. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. section 674 of the Corporations Act; and
3. as at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) or 708A(8) of the Corporations Act.

Contact details:

Kathryn Davies
Company Secretary
Tel: +61 (0)3 5339 0704
daviesk@integraldiagnostics.com.au

About IDX:

Integral Diagnostics (IDX) is a leading provider of medical imaging services across Australia and New Zealand. The Company provides state of the art diagnostic services to patients and their referrers at 53 radiology clinics, including 13 hospital sites. IDX employs some of Australasia's leading radiologists and nuclear medicine specialists in a unique medical leadership model that ensures quality patient care, service and access. Good medicine is good business.